

Pharmactive advisory panel to support business development globally

April 20, 2021 | News

Pharmactive enters a Nutra meets pharma initiative with mental health and metabolic balance formulations



Spanish Company, Pharmactive Biotech, S.L., is tapping into the pharmaceutical market with its leading branded ingredients, such as affron® [saffron extract](#), for supporting mental health. The company has appointed Paul Clayton, PhD as Chair of its scientific advisory board. Together with Pharmactive's medical advisor, Carlos Galmarini, MD, PhD, they will lead this strategic move for Pharmactive.

Affron® is a premium saffron ingredient standardized to 3.5% Lepticrosalides®, by HPLC, a complex of bioactive compounds responsible for the beneficial properties and organoleptic properties of affron®. It is backed by 6 human clinical studies that have shown to improve mood in healthy consumers with occasional stress and anxiety, and to improve sleeplessness.

The following main mechanisms of action of affron® have been identified:

- **Inhibition of the reuptake mechanism of dopamine, norepinephrine, and serotonin**, increasing the concentrations of these neurotransmitters in the synaptic cleft of neurons, thereby improving mood balance.
- **Antioxidant effect** against the excessive oxidative stress produced during occasional anxiety or stress processes in the central nervous system.
- **Anti-inflammatory action** in stressed neural tissue, decreasing hippocampal levels of apoptotic biomarkers and stress signal molecules.

"Including high-level medical and natural science experts on the advisory board enables the company to combine and reconcile the two worlds of pharma and nutraceuticals, to benefit both consumers and medical practitioners and will help the pharmaceutical business provide greater value to their patrons," says Jean-Marie Raymond, CEO at Pharmactive.

Paul Clayton is a clinical pharmacologist and pharmacological nutritionist. He is the former Chair of the Forum on Food & Health (UK) and a former Senior Scientific Advisor to the UK government's Committee on the Safety of Medicines. Carlos Galmarini is the Founder and CEO of Topazium Smart Medicine, a biomedical and pharmaceutical artificial intelligence platform based in Madrid, Spain.